- Reece Pharmaceuticals (RCE) has enlisted CMAX Clinical Research in South Australia to carry out a Phase 1 clinical study of its RECCE 327 compound
- The randomised, double blind, placebo-controlled single-ascending dose trial will assess 48 healthy adult subjects
- It has been designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of RECCE 327
- With a formal recruitment process to open shortly, first subjects are expected to be screened in the fourth quarter of 2020
- Reece Pharmaceuticals closed 2.2 per cent in the green for $1.62 per share
Recce Pharmaceuticals (RCE) has enlisted CMAX Clinical Research in South Australia to carry out a Phase 1 clinical study of its RECCE 327 compound.
The randomised, double blind, placebo-controlled trial will assess 48 healthy adult subjects, and has been designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of RECCE 327 following intravenous administration.
A formal recruitment process for the independent trial is expected to open shortly, with initial subject screening anticipated in the fourth quarter of this year.
Commenting on the upcoming study, John Prendergast, Non-Executive Chairman of Recce Pharmaceuticals, drew attention to CMAX’s impressive global regulatory history, database and diverse team of experts.
“As we prepare to enroll patients in our Phase I study, a critical milestone for Recce, we are confident in CMAX’s ability to leverage its established recruitment networks and deliver exceptional quality data,” he said.
Located adjacent to The Royal Adelaide Hospital, CMAX is one of Australia’s longest-running clinical trial facilities and has more than 30,000 registered patient volunteers on file.
Recce also noted that South Australia has one of the lowest rates of COVID-19 infection nation-wide, which makes it an attractive location for the company’s clinical studies.
“The need for new classes of anti-infectives has never been greater,” said Jane Kelly, CEO of CMAX Clinical Research.
“We are committed to supporting innovative medical research and look forward to assessing RECCE 327’s clinical utility in the infectious disease treatment landscape, through this Phase 1 human clinical study,” she added.
RECCE 327 is a broad-spectrum synthetic antibiotic that uses synthetic polymer technology to treat blood infections and sepsis brought on by Escherichia coli and Staphylococcus aureus bacteria.
Recce Pharmaceuticals says it is the first new class of antibiotic in more than 30 years and is effective against both Gram-negative and Gram-positive bacteria, with an ability to maintain its potency even after repeated use.
Reece Pharmaceuticals closed 2.2 per cent in the green for $1.62 per share.